证券日报网讯万邦医药（301520）11月12日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司的股东人数为8212户。 ...

Core Points - Wanbang Pharmaceutical announced a change in its sponsor representatives, with Wang Lu and Xu Cheng appointed as the new continuous supervision sponsors [2] Group 1 - The company has officially updated its sponsor representatives in a recent announcement [2]

Core Viewpoint - Beilong Precision reported that as of October 31, the number of shareholders reached 8,823 [2] Company Summary - The company actively engages with investors through platforms, indicating a commitment to transparency and communication [2] - The increase in shareholder count may reflect growing interest in the company's performance and potential [2]

Core Viewpoint - Wanbang Medical (301520) reported that as of October 31, 2025, the number of shareholders is expected to reach 8,277 [1] Company Summary - Wanbang Medical has engaged with investors through an interactive platform, providing insights into its shareholder structure [1] - The company is projecting a specific number of shareholders by a future date, indicating a focus on shareholder engagement and growth [1]

本次保荐代表人变更后，公司持续督导的保荐代表人为王璐先生和徐诚先生， 继续履行相关的职责和义务，持续督导期至中国证券监督管理委员会和深圳证券 交易所规定的持续督导义务结束为止。 公司董事会对傅德福先生在公司首次公开发行股票并在创业板上市及持续 督导期间所做出的贡献表示衷心感谢！ 特此公告。 安徽万邦医药科技股份有限公司董事会 证券代码：301520 证券简称：万邦医药 公告编号：2025-057 安徽万邦医药科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于近日收到保荐机构 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"）出具的《关 于安徽万邦医药科技股份有限公司变更持续督导保荐代表人的函》。民生证券股 份有限公司（以下简称"民生证券"）为公司首次公开发行股票并在创业板上市 项目的保荐机构和持续督导机构，王璐先生和傅德福先生为公司持续督导保荐代 表人，法定持续督导期限至 2026 年 12 月 31 日。 国联民生证券股份有限公司已完成对民生证券的合 ...

Group 1 - The core point of the article is that Wanbang Pharmaceutical (301520) has completed its share repurchase plan, which was set to expire on October 22, 2025 [1] - The company repurchased a total of 404,900 shares, which represents 0.61% of its total share capital [1]

Core Insights - Wanbang Medical (301520) reported that as of October 20, 2025, the number of shareholders is 8,174 [1] Company Summary - Wanbang Medical has a total of 8,174 shareholders as of the specified date [1]

关于回购股份实施结果暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日召开第二届董事会第十五次会议和第二届监事会第九次会议，审议通过了《关 于使用部分超募资金回购公司部分股份方案的议案》，同意公司使用超募资金以 集中竞价交易方式回购公司部分社会公众股股份并用于股权激励计划或员工持 股计划，用于回购股份的总金额为1,500万元-3,000万元，回购价格不超过60.62 元/股（含），具体回购股份的数量及金额以回购期满时实际回购的股份数量及金 额为准。本次回购的实施期限为董事会审议通过回购方案之日起 12 个月内。具 体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn，下同）上披露的《关 于使用部分超募资金回购公司部分股份方案的公告》（公告编号：2024-040）和 《回购报告书》（公告编号：2024-042）。 鉴于公司已实施完成 2024 年前三季度权益分派方案，根据相关规定，公司 自权益分派除权除息之日即 2025 年 1 月 24 ...

Core Viewpoint - Wanbang Pharmaceutical (301520.SZ) has stated that its current research and development focus does not include influenza medications [1] Group 1 - The company is not involved in the development of flu drugs at this time [1]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the third quarter of 2023, indicating potential challenges in its business operations [1] Financial Performance - Revenue for the first three quarters of 2023 was approximately 209 million yuan, a year-on-year decrease of 28.6% [1] - Net profit attributable to shareholders was about 33.11 million yuan, reflecting a year-on-year decline of 57.44% [1] - Basic earnings per share were 0.5 yuan, down 57.26% compared to the previous year [1] Business Strategy - The company is actively monitoring opportunities in the upstream and downstream industrial layout of its main business [1] - The company emphasizes strict compliance with relevant laws and regulations, asserting that there are no undisclosed significant matters [1] - The company commits to timely information disclosure regarding any significant matters that may arise in the future [1]